Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy-Reference-Cited by-同舟云学术

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

Published:2011-08-08 Issue:8 Volume:130 Page:1948-1959
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Farsaci Benedetto,Higgins Jack P.,Hodge James W.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

2. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial;Demetri;Lancet,2006

3. National Cancer Institute http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=8430114

4. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin Cancer Res,2003

5. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels;Osusky;Angiogenesis,2004

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety;Life Sciences;2024-06

2. Self‐Delivered Transformable Nanosystem Capable of Enhancing Photodynamic Effectiveness and Multi‐Target Ameliorating Immunosuppression for Treatment of Breast Cancer and Lung Metastasis;Advanced Functional Materials;2024-05-09

3. Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model;International Journal of Molecular Sciences;2024-02-02

4. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?;Pharmacology & Therapeutics;2023-09

5. Immunotherapies targeting tumor vasculature: challenges and opportunities;Frontiers in Immunology;2023-09-01